Stock reports › US › Healthcare
UnitedHealth Group Incorporated (UNH) stock analysis
UnitedHealth recovers to $402.94 with earnings beats and rising estimates, still far below its all-time high
UnitedHealth Group closed at 402.94 on Nov 11, 2026, up 22.06% year to date but 36.12% below its all-time high of 630.73. The last quarter beat EPS consensus by 13.29% and next year's consensus EPS growth is 13.67%, though revenue growth is modest and margins are thin. Implied volatility is low relative to its 52-week range, and the next earnings report is expected Jan 20, 2027.
- Price: 389.68
- Market Cap (USD): $351.49B
- P/E: 22.13×
- Fwd P/E: 16.88×
- Div Yield: 2.32%
- 1Y Return: 21.07%
- Next Earnings: Jan 20, 2027
- Mean Target: 478.25
- Rating: Buy
Bull case
- Latest quarterly EPS of 4.69 beat consensus of 4.14 by 13.29% on Oct 13, 2026, extending the EPS beat streak to 5.
- Free cash flow over the trailing twelve months is $22.83B-scale (22.83B), up 31.40% year over year, a free cash flow yield of 6.28% in the 75th percentile of US Healthcare.
- Forward P/E of 17.49 is in line with the industry median of 17.49 and below the sector median of 18.68, while consensus EPS estimates were revised up 4.00% over 30 days.
Bear case
- Trailing EPS growth is -8.55% year over year and the 3-year EPS CAGR is -14.52%, with annual diluted EPS falling from 23.86 in 2023 to 13.23 in 2025.
- Operating margin is 5.32%, in the 23rd percentile of the sector, and fell 0.74% over the past year; revenue growth of 3.33% sits in the 19th percentile.
- Earnings reactions have been large: the 8-quarter maximum move was 27.30% and the Jan 27, 2026 report brought a -16.39% move, while the current ratio is 0.74×.
What to watch
- Next earnings on Jan 20, 2027 (before market open, not yet confirmed); consensus EPS is 2.28.
- Ex-dividend date Dec 7, 2026 for the 2.32 quarterly dividend, payable Dec 15, 2026.
- The 20-day average at 407.51 and 20-day high of 426.55 as nearby resistance; 50-day average at 391.19 and 20-day low of 388.00 as support.
- The 52-week high of 461.62 (83 days ago) and the 200-day average at 365.31.
General
UnitedHealth is a large US healthcare enterprise whose shares have rebounded sharply from the 2025-2026 lows. Earnings are beating expectations and estimates are rising, but margins are thin and the stock remains well below its peak. Analysts are broadly positive.
The business
Per its profile, UnitedHealth operates four segments: UnitedHealthcare, Optum Health, Optum Insight and Optum Rx, with 390,000 employees. In fiscal 2025, premiums were 352.23B, or 78.70% of revenue. Trailing revenue is $449.66B with net income of 15.88B and a net margin of 3.53%.
Valuation in context
Price to earnings is 22.88× trailing and 17.49× forward, in the 43rd percentile of US Healthcare on forward P/E. Price to sales of 0.81× is in the 10th percentile. The free cash flow yield is 6.28% and the dividend yield is 2.25%.
Analysts and market signals
As of Nov 11, 2026, 43 analysts rate it Buy, 7 Hold and 2 Sell, and the mean target of 478.25 implies 18.69% upside. No upgrades or downgrades occurred in the past 30 days. Short interest is low at 1.55% of float as of Oct 30, 2026.
Long-term investor
Revenue has compounded at 11.35% over three years, but earnings have fallen since 2023 and margins have compressed. Cash generation, returns on capital and shareholder payouts remain solid, and estimates point to a recovery.
Growth durability
Annual revenue rose from 257.14B in 2020 to 447.57B in 2025, but diluted EPS fell from 23.86 in 2023 to 13.23 in 2025. Q4 FY2025 EPS was only 0.011, while Q1 to Q3 FY2026 EPS were 6.9, 6.05 and 4.56. Next-year EPS growth is 13.67%, in the 72nd percentile.
Returns and balance sheet
ROIC is 13.14% and ROE is 16.39%, above sector medians of 10.62% and 10.81%. Total debt is 74.33B against cash of 28.55B, with net debt to EBITDA of 1.64× and interest coverage of 6.21×. The current ratio is 0.74×.
Capital return and ownership
The dividend has grown for 16 years, with 10.90% 3-year growth, a 51.71% payout ratio and a quarterly payment of 2.32. Fiscal 2025 buybacks were 5.54B, down from 9.00B in 2024. Institutions hold 88.55%; insiders had one sale and no buys in 90 days.
Swing trader
The stock is in an uptrend above its 50- and 200-day averages but slipped below its 20-day average with a MACD below its signal line. Momentum is neutral and the next earnings report is 70 days away.
Trend and momentum
Price of 402.94 is 3.00% above the 50-day average (391.19) and 10.30% above the 200-day (365.31), with a golden cross on May 18, 2026. It is 1.12% below the 20-day average (407.51). RSI is 52.21, MACD histogram -1.62 and ADX 25.06, a moderate trend.
Levels and recent sessions
The range since Oct 22 runs from a 426.55 high to a 388.00 low. A Nov 4 spike to 416.02 was followed by a drop to 395.72 on Nov 5 on 6.9M shares, then a recovery to 405.12 on Nov 10. Nov 11 volume of 4.1M was 0.71× average.
Risk and flow
ATR is 11.40, or 2.83% of price, and 30-day historical volatility is 27.33%. Short interest is 1.55% of float with 2.87 days to cover. Analysts reiterated ratings in October, with Baird cutting its target to 427 from 453 on Oct 14.
Options
Implied volatility is moderate and low within its 52-week range, trading above realized volatility. Options are highly liquid, and call activity dominates volume.
Volatility level
30-day implied volatility is 31.18% with an IV rank of 20 and IV percentile of 42, against a 52-week range of 25.13% to 55.88%. It sits 3.8 points above 30-day realized volatility, a ratio of 1.14×, so premium is modestly rich versus realized.
Term structure and expected moves
The term structure is in contango, with 90-day IV at 32.64%, 1.5 points above 30-day. Skew is +4.2 points. The market implies a 4.32% move over 7 days and 8.94% over 30 days. The 30-day expiry of Dec 11, 2026 falls before the next earnings.
Earnings and premium yields
Average earnings moves were 8.00% over four quarters and 9.27% over eight, with a median of 5.95%. The last implied earnings move was 7.49% versus an actual 4.52%. A 30-delta put at 385.00 yields 22.98% annualized and a 30-delta call at 425.00 yields 17.57%; an ex-dividend date falls before expiry.
Analysis written November 12, 2026 from Qanvo data as of November 11, 2026. AI-generated, for information only; not investment advice.